Gregory McAllister
Novartis
31 Papers
193 Citations
Gregory McAllister is an academic researcher from Novartis. The author has contributed to research in topics: CRISPR & Cas9. The author has an hindex of 20, co-authored 31 publications.
Chat about Author
Papers
p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
Robert J. Ihry,Kathleen A. Worringer,Max R. Salick,Elizabeth Frias,Daniel J. Ho,Kraig M. Theriault,Sravya Kommineni,Julie Chen,Marie Sondey,Chaoyang Ye,Ranjit Randhawa,Tripti Kulkarni,Zinger Yang,Gregory McAllister,Carsten Russ,John S. Reece-Hoyes,William C. Forrester,Gregory R. Hoffman,Ricardo E. Dolmetsch,Ajamete Kaykas +19 more
TL;DR: The results indicate that Cas9 toxicity creates an obstacle to the high-throughput use of CRISPR/Cas9 for genome engineering and screening in hPSCs, and as h PSCs can acquire P53 mutations14, cell replacement therapies using CRISpr/cas9-enginereed hPSCS should proceed with caution, and such engineered hPSPs should be monitored for P53 function.
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald,Antoine de Weck,Michael R. Schlabach,Eric Billy,Konstantinos J. Mavrakis,Gregory R. Hoffman,Dhiren Belur,Deborah Castelletti,Elizabeth Frias,Kalyani Gampa,Javad Golji,Iris Kao,Li Li,Philippe Megel,Thomas A. Perkins,Nadire Ramadan,David A. Ruddy,Serena J. Silver,Sosathya Sovath,Mark Stump,Odile Weber,Roland Widmer,Jianjun Yu,Kristine Yu,Yingzi Yue,Dorothee Abramowski,Elizabeth Ackley,Rosemary Barrett,Joel Berger,Julie L. Bernard,Rebecca Billig,Saskia M. Brachmann,Frank Buxton,Roger Caothien,Justina X. Caushi,Franklin Chung,Marta Cortes-Cros,Rosalie deBeaumont,Clara Delaunay,Aurore Desplat,William Duong,Donald A. Dwoske,Richard S. Eldridge,Ali Farsidjani,Fei Feng,JiaJia Feng,Daisy Flemming,William C. Forrester,Giorgio G. Galli,Zhenhai Gao,François Gauter,Veronica Gibaja,Kristy Haas,Marc Hattenberger,Tami Hood,Kristen Hurov,Zainab Jagani,Mathias Jenal,Jennifer Johnson,Michael D. Jones,Avnish Kapoor,Joshua M. Korn,Jilin Liu,Qiumei Liu,Shumei Liu,Yue Liu,Alice T. Loo,Kaitlin J. Macchi,Typhaine Martin,Gregory McAllister,A. B. Meyer,Sandra Mollé,Raymond Pagliarini,Tanushree Phadke,Brian Repko,Tanja Schouwey,Frances Shanahan,Qiong Shen,Christelle Stamm,Christine Stephan,Volker M. Stucke,Ralph Tiedt,Malini Varadarajan,Kavitha Venkatesan,Alberto C. Vitari,Marco Wallroth,Jan Weiler,Jing Zhang,Craig Mickanin,Vic E. Myer,Jeffery A. Porter,Albert Lai,Hans Bitter,Emma Lees,Nicholas Keen,Audrey Kauffmann,Frank Stegmeier,Francesco Hofmann,Tobias Schmelzle,William R. Sellers +99 more
TL;DR: A large-scale RNAi screen is conducted in which viability effects of mRNA knockdown were assessed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features.
632
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
Gregory R. Hoffman,Rami Rahal,Frank Buxton,Kay Xiang,Gregory McAllister,Elizabeth Frias,Linda Bagdasarian,Janina Huber,Alicia Lindeman,Dongshu Chen,Rodrigo Romero,Nadire Ramadan,Tanushree Phadke,Kristy Haas,Mariela Jaskelioff,Boris G. Wilson,Matthew J. Meyer,Veronica Saenz-Vash,Huili Zhai,Vic E. Myer,Jeffery A. Porter,Nicholas Keen,Margaret E. McLaughlin,Craig Mickanin,Charles W. M. Roberts,Frank Stegmeier,Zainab Jagani +26 more
TL;DR: This study provides important mechanistic insight into the BRM/BRG1 synthetic lethal relationship, shows this finding translates in vivo, and highlights BRM as a promising therapeutic target for the treatment BRG1-mutant cancers.
395
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
Christina H. Eng,Zuncai Wang,Diane Tkach,Lourdes Toral-Barza,Savuth Ugwonali,Shanming Liu,Stephanie Fitzgerald,Elizabeth George,Elizabeth Frias,Nadire Cochran,Rowena De Jesus,Gregory McAllister,Gregory R. Hoffman,Kevin Bray,Luanna Lemon,Judy Lucas,Valeria Fantin,Robert T. Abraham,Leon Murphy,Beat Nyfeler +19 more
TL;DR: Data indicate that KRAS mutation status does not predict cell-autonomous addiction to autophagy, and addresses a long-standing question regarding the mechanism of chloroquine, a lysosomotropic agent often used as a pharmacological tool to evaluate the response to macroautophagy inhibition.
222
DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery
Chaoyang Ye,Daniel J. Ho,Marilisa Neri,Chian Yang,Tripti Kulkarni,Ranjit Randhawa,Martin Henault,Nadezda Mostacci,Pierre Farmer,Steffen Renner,Robert J. Ihry,Leandra Mansur,Caroline Gubser Keller,Gregory McAllister,Marc Hild,Jeremy L. Jenkins,Ajamete Kaykas +16 more
TL;DR: DRUG-seq provides a powerful tool for comprehensive transcriptome readout in a high-throughput screening environment and captures common mechanisms, as well as differences between compound treatment and CRISPR on the same target.